MULTIBODY

Live / Registered — Cancelled — Section 71 (as of 08 Nov 2024)

What this means for you

Registered since 24 Apr 2018. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
79209028
Registration number
5450600
Mark type
Stylized text
Filed
21 Oct 2016
Published for opposition
06 Feb 2018
Registered
24 Apr 2018
Attorney of record
Christopher J. Schulte

Goods and services

  • Class 001 — Chemicals: Chemicals used in industry and science; chemicals for laboratory research purposes; monoclonal antibodies and antibody fragments for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes; monoclonal antibody reagents for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes for use in the manufacture of therapeutic products
  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; monoclonal antibodies for therapeutic purposes, namely, therapeutic agents for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the manufacture of therapeutic products
  • Class 040 — Treatment of materials: Treatment and transformation of materials, namely, custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments
  • Class 042 — Scientific and technological services: Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; research and development in the field of antibodies and antibody fragments; medical research laboratory services relating to antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific research relating to the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design

Owner

Prosecution history

  • 22 Jan 2026 — TOTAL INVALIDATION PROCESSED BY THE IB
  • 30 Dec 2025 — TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
  • 30 Dec 2025 — INVALIDATION PROCESSED
  • 08 Jul 2025 — TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
  • 03 Jun 2025 — LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
  • 08 Nov 2024 — CANCELLED SECTION 71
  • 08 Nov 2024 — RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
  • 27 Oct 2023 — LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
  • 19 Aug 2023 — RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
  • 24 Apr 2023 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
  • 07 Sept 2018 — FINAL DECISION TRANSACTION PROCESSED BY IB
  • 09 Aug 2018 — FINAL DISPOSITION NOTICE SENT TO IB
  • 09 Aug 2018 — FINAL DISPOSITION PROCESSED
  • 24 Jul 2018 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
  • 24 Apr 2018 — REGISTERED-PRINCIPAL REGISTER

View this trademark record on Marksy